An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy.
Phase of Trial: Phase II
Latest Information Update: 16 May 2013
At a glance
- Drugs Topsalysin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 30 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 May 2008 The expected completion date for this trial is now 1 Sep 2010 according to ClinicalTrials.gov.